Optical Coherence Tomography Comparison of Percutaneous Coronary Intervention Among Plaque Rupture, Erosion, and Calcified Nodule in Acute Myocardial Infarction

Khalifa, Amir Kh. M.; Kubo, Takashi; Ino, Yasushi; Terada, Kosei; Emori, Hiroki; Higashioka, Daisuke; Katayama, Yosuke; Takahata, Masahiro; Shimamura, Kazuo; Shiono, Yasutsugu; Matsuo, Yoshiki; Tanaka, Atsushi; Hozumi, Takeshi

doi:10.1253/circj.cj-20-0014

Cited by 29 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, all patients received IVUS guided PCI, which may have reduced the risk of medial disruption and subsequent excessive neointimal hyperplasia. In addition, delayed in-stent strut neointimal coverage [5] and stent malapposition [9] were often identified in heavily calcified lesions where CN and stent struts are exposed to blood flow, subsequent thrombus formation and recurrence of ACS (e.g., majority are in-stent CN, minority are stent thrombosis [10]), or a silent thrombus with organization ( Fig. 1).…”

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes

Sato¹,

Finn²,

Virmani³

2021

Atherosclerosis

View full text Add to dashboard Cite

Section: Contents Lists Available At Sciencedirectmentioning

confidence: 99%

Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes

Sato¹,

Finn²,

Virmani³

2021

Atherosclerosis

View full text Add to dashboard Cite

“…These favorable results partly derived from less calci ed lesion selected by experienced operators. In the pathogenesis of ACS, the calci ed plaque is the least frequent etiology, but associated with aggressive lesion preparation which entails predilatation with a high-pressure post-balloon, a large-sized balloon, or a cutting balloon [28,29]. Accordingly, the potential risk of coronary dissection inevitably ramp up due to this approach to achieve su cient lumen area.…”

Section: Discussionmentioning

confidence: 99%

Feasibility and Safety of Drug-Coated Balloon-Only Angioplasty for De Novo Ostial Lesions of Left Anterior Descending Artery: Two Center’s Retrospective Study

Li¹,

Ding²,

Wang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background:There is limited evidence of drug-coated balloon (DCB) only angioplasty in percutaneous treatment of complex de novo ostial coronary lesions. The major objective of our study is to explore the feasibility and test safety of this innovative approach in ostial lesions of left anterior descending artery (LAD). Methods:Patients treated with paclitaxel DCB or second-generation drug-eluting stent (DES) were retrospectively enrolled from two different large centers. The primary endpoints were defined as major adverse cardiovascular events (MACE) composed of cardiovascular death, target lesion revascularization (TLR), target vessel revascularization (TVR), and recurrent myocardial infarction related to target artery occlusion. Cox regression analysis were used to identify risk factors for MACE and propensity score matching is performed to minimize the selection bias.Results:A total of 53 patients were treated with paclitaxel DCB and 336 patients with DES in ostial lesions of LAD were recruited. In accordance with propensity score matching, 49 patients treated with DCB-only coordinated with 49 ones with the strategy of DES. After average follow-up time of 10 months, the rate of MACE trended to lower in DCB-only angioplasty treatment arm and triggered by post-procedure TLR (MACE: 6% vs. 4%, p=0.65; TLR: 2% vs. 4%, p=0.56). Cox regression analysis indicated that not DCB-only angioplasty was considered as an independent risk factor for adverse events after adjustment for cofound risk factors (HR: 1.748, p=0.48).Conclusions:Use of DCB-only approach in treatment of isolated ostial LAD disease could be an innovative and safe strategy without additional risk of aggressive progression of left circumflex artery.

show abstract

“…Intensive treatment with high-intensity statins reduces the incidence of cardiovascular events after acute myocardial infarction (AMI) 1) . AMI is mainly characterized by the rupture of a lipid-rich vulnerable atherosclerotic plaque 2) . Matrix metalloproteinases (MMPs), namely MMP-2 and MMP-9, have been localized in atherosclerotic plaques, which are characterized by a lipid core covered with a fibrous cap in which inflammatory cells such as macrophages and T-lymphocytes are accumulated [3][4][5] ,with the metalloproteinases being a family of zinc-dependent proteases that are produced by a variety of cell types, including endothelial cells, smooth muscle cells, and monocytes.…”

Section: Introductionmentioning

confidence: 99%

Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases–INVITATION Trial–

Shirakawa

Fujisue

Nakamura

et al. 2022

JAT

View full text Add to dashboard Cite

The official journal of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases Original Article Aim: Matrix metalloproteinases (MMPs) play critical roles in acute myocardial infarction (AMI). This trial was conducted to determine the potential effects of higher-dose rosuvastatin on circulating MMP levels in patients with AMI.Methods: This was a multicenter, open-label, 1:1 randomized, parallel-group study. Patients with AMI were randomly assigned to the appropriate-dose group (10 mg rosuvastatin once daily) or the low-dose group (2.5 mg rosuvastatin once daily) within 24 hours after percutaneous coronary intervention. MMP-2 and MMP-9 levels were measured on day 1 and at week 4, 12, and 24 after enrollment. The primary endpoint was the change in MMP levels at 24 weeks after enrollment. The secondary endpoints were change in MMP levels at day 1 and weeks 4 and 12 after enrollment. Results: Between August 2017 and October 2018, 120 patients with AMI from 19 institutions were randomly assigned to either the appropriate-dose or the low-dose group. There were 109 patients who completed the 24-week follow-up. The primary endpoint for both MMP-2 and MMP-9 was not significantly different between the two groups. The change in the active/total ratio of MMP-9 at week 12 after baseline was significantly lower in the appropriate-dose group compared with the low-dose group (0.81 [−52.8-60.1]% vs. 70.1 [−14.5-214.2]%, P 0.004), while the changes in MMP-2 were not significantly different between the two groups during the study period. Conclusions: This study could not demonstrate the superiority of appropriate-dose of rosuvastatin in inhibiting serum MMPs levels in patients with AMI.

show abstract

Optical Coherence Tomography Comparison of Percutaneous Coronary Intervention Among Plaque Rupture, Erosion, and Calcified Nodule in Acute Myocardial Infarction

Cited by 29 publications

References 16 publications

Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes

Calcified nodule: A rare but important cause of acute coronary syndrome with worse clinical outcomes

Feasibility and Safety of Drug-Coated Balloon-Only Angioplasty for De Novo Ostial Lesions of Left Anterior Descending Artery: Two Center’s Retrospective Study

Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases–INVITATION Trial–

Contact Info

Product

Resources

About